PRINCETON, N.J., May 18, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX), a women's healthcare company, today announced the content of the official minutes from its Type A meeting with the U.S. Food and Drug Administration (FDA) held on April 16, 2018 to discuss the complete...
PRINCETON, N.J., Dec. 22, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the U.S. Food and Drug Administration (FDA) issued a complete response letter (CRL) in response to the New Drug Application (NDA) resubmission for the...
The abstract was accepted by ACOG and will be presented from May 4th – May 6th, 2022 PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that data from the company’s first-year of postmarketing pharmacovigilance...
Partners with Award-Winning Director Maya Albanese “Patch and Play” introduces the features of the Twirla (levonorgestrel and ethinyl estradiol) transdermal system, while highlighting the power of female friendships PRINCETON, N.J., March 31, 2022 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc....
PRINCETON, N.J., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (Nasdaq:AGRX) a women's health specialty pharmaceutical company focused on the development and commercialization of new prescription contraceptive products, today announced that Al Altomari, President and Chief Executive...
Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March...
Twirla ® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J. , Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX) (Agile or the Company), a forward-thinking women’s healthcare company, today announced that the U.S....
Company Plans to Appeal to the FDA’s Office of New Drugs PRINCETON, N.J. , July 24, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq:AGRX) (the “Company”), a women’s healthcare company, today announced that the Office Director of the FDA’s Office of Drug Evaluation III (ODEIII) has...